Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Dakota Oxervate Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.02.73

    Oxervate (cenegermin-bkbj) Coverage Criteria

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.02.73 alerts

    Get alerted when Policy 05.02.73 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for Oxervate for members with Stage 2 or Stage 3 neurotrophic keratitis, subject to clinical criteria, specialist involvement, and applicable benefit exclusions.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyOxervate (cenegermin-bkbj) Coverage Criteria
    Policy CodePolicy 05.02.73
    Change TypeNo material change
    Effective DateApr 9, 2025
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionOxervate must be prescribed by or used in consultation with an ophthalmologist or optometrist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Neurotrophic keratitisCovered indication
    Stage 2 or 3Eligible stages

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    16 weeks
    Initial authorization
    8 weeks/eyeTherapy duration
    8 kits/eyeLifetime quantity limit

    Coverage Criteria

    Initial therapy: neurotrophic keratitis

    Covered for initial approval when all of the following are met.

    Initial approval for neurotrophic keratitis

    • Eligible disease stage

      • The member has Stage 2 neurotrophic keratitisStage 2
      • The member has Stage 3 neurotrophic keratitisStage 3
    • Persistent defect or ulceration refractory to treatment: The member has a persistent epithelial defect or corneal ulceration lasting at least 2 weeks and refractory to one or more conventional nonsurgical treatmentsAt least 2 weeks duration

      Examples of conventional nonsurgical treatment include preservative-free artificial tears.

    • Reduced corneal sensitivity: There is evidence of decreased corneal sensitivity within the area of the persistent epithelial defect or corneal ulcer and outside the area of the defect in at least one corneal quadrantWithin the defect and outside the defect in at least one corneal quadrant

      Examples of assessment methods include the cotton swab method, Cochet-Bonnet contact aesthesiometer, and CRCERT-Belmonte non-contact aesthesiometer.

    • No prior course in affected eye: The member has not received a previous 8-week course of Oxervate in the affected eyeNo previous 8-week course

    A previous 8-week course of Oxervate in the affected eye precludes initial approval under this policy.

    Provider Actions and Authorization Rules

    Prior Authorization

    Ophthalmic Specialist Involvement

    Oxervate must be prescribed by, or used in consultation with, an ophthalmologist or optometrist.

    Prior Authorization

    Initial Authorization Duration

    Authorization may be granted for 16 weeks, providing 8 weeks of therapy per affected eye, for qualifying Stage 2 or Stage 3 neurotrophic keratitis.

    • Maximum initial authorization: 16 weeks
    • Therapy duration: 8 weeks per affected eye
    Documentation Required

    Clinical Background

    Oxervate (cenegermin-bkbj) is a recombinant human nerve growth factor indicated for the treatment of neurotrophic keratitis. Coverage focuses on members with Stage 2 or Stage 3 disease accompanied by a persistent epithelial defect or corneal ulceration and reduced corneal sensitivity; this policy addresses the clinical criteria for initial treatment authorization.

    Definitions

    Oxervate
    DrugOxervate (cenegermin-bkbj)
    Drug classRecombinant human nerve growth factor
    IndicationTreatment of neurotrophic keratitis
    Stage 2 and Stage 3 neurotrophic keratitis
    Eligible diseaseNeurotrophic keratitis
    Eligible stagesStage 2 or Stage 3
    ApplicationEligible for initial Oxervate approval when the policy criteria are met

    Initial Approval Criteria

    Initial approval

    Authorization of 16 weeks may be granted when all of the following criteria are met.

    Oxervate initial approval

    • Eligible disease stage

      • The member has Stage 2 neurotrophic keratitisStage 2
      • The member has Stage 3 neurotrophic keratitisStage 3
    • The member has persistent epithelial defects or corneal ulceration of at least 2 weeks duration refractory to one or more conventional nonsurgical treatmentsAt least 2 weeks duration

    Step Therapy Requirements

    StepRequirementExample
    1One or more conventional nonsurgical treatments must have been tried and failed; the persistent epithelial defect or corneal ulceration must remain refractory to treatment.Preservative-free artificial tears

    Quantity Limits

    Oxervate quantity limit
    Quantity limit8 kits
    Applies perAffected eye
    Lifetime limitPer lifetime
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyOxervate (cenegermin-bkbj) Coverage Criteria
    Policy CodePolicy 05.02.73
    Change TypeNo material change
    Effective DateApr 9, 2025
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionOxervate must be prescribed by or used in consultation with an ophthalmologist or optometrist.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and Authorization RulesClinical BackgroundDefinitionsInitial Approval CriteriaStep Therapy RequirementsQuantity Limits

    Failure of Conventional Nonsurgical Treatment

    The affected eye must have a persistent epithelial defect or corneal ulceration of at least 2 weeks’ duration that is refractory to one or more qualifying conventional nonsurgical treatments.

    • Example of qualifying treatment: preservative-free artificial tears
    Documentation Required

    Clinical Documentation for Initial Approval

    For initial approval, submit documentation establishing the diagnosis and required clinical findings, including the disease stage, duration and location of the persistent epithelial defect or corneal ulceration, failure of conventional nonsurgical treatment, decreased corneal sensitivity, and relevant treatment history.

    • Document Stage 2 or Stage 3 neurotrophic keratitis.
    • Document a persistent epithelial defect or corneal ulceration lasting at least 2 weeks.
    • Document decreased corneal sensitivity within the defect and outside the defect in at least one corneal quadrant, including the testing method used (for example, cotton swab, Cochet-Bonnet, or CRCERT-Belmonte).
    • Document that the member has not received a previous 8-week course of Oxervate in the affected eye.
    Denial Risk

    Failure to Meet Initial Clinical Criteria

    Initial authorization is at risk of denial when the required disease stage, persistent epithelial defect or corneal ulceration, minimum duration, failure of conventional nonsurgical treatment, decreased corneal sensitivity, or treatment-history criteria are absent or not documented.

    • The condition must be Stage 2 or Stage 3 neurotrophic keratitis.
    • The defect or ulceration must be present for at least 2 weeks and refractory to conventional nonsurgical treatment.
    • Required evidence of decreased corneal sensitivity must be documented.
    • A previous 8-week course of Oxervate in the affected eye disqualifies the request.
    Denial Risk

    Lifetime Quantity Limit Exceeded

    Requests exceeding the lifetime quantity limit are at risk of denial.

    • Limit: 8 kits per affected eye per lifetime
    • 1 kit contains 7 × 1 mL multiple-dose vials

    Examples of conventional nonsurgical treatment include preservative-free artificial tears.

  1. There is evidence of decreased corneal sensitivity within the area of the persistent epithelial defect or corneal ulcer and outside the area of the defect in at least one corneal quadrantWithin the defect and outside the defect in at least one corneal quadrant

    Examples of assessment methods include the cotton swab method, Cochet-Bonnet contact aesthesiometer, and CRCERT-Belmonte non-contact aesthesiometer.

  2. The member has not received a previous 8-week course of Oxervate in the affected eyeNo previous 8-week course